Elevated Fibrinogen‐Fibrin Degradation Products (FDP) in Serum of Colorectal Cancer Patients

Abstract

Serum fibrinogen‐fibrin degradation product (FDP) levels of healthy control subjects and of patients with colorectal cancer have been measured by DR‐70® ELISA in Frankfurt, Germany (Germany study) and in Tustin, California (U.S. study). Serum FDP levels of patients with colorectal cancer were significantly higher than those of the healthy controls. The median serum FDP levels in healthy control groups of the German and U.S. studies were, respectively, 0.37 µg/mL and 0.61 µg/mL. The median serum FDP levels in the colorectal cancer groups of the German and U.S. studies were, respectively, 1.25 µg/mL and 1.60 µg/mL. The results are consistent with enhanced fibrinolysis in serum of patients with colorectal cancer.